Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

NCT05665062 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

CLL/SLL
NHL
Mantle Cell Lymphoma
Follicular Lymphoma
Large B-cell Lymphoma
Indolent B-Cell Non-Hodgkin Lymphoma
Diffuse Large B Cell Lymphoma

Interventions

DRUG: SYNCAR-001
DRUG: STK-009
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

Synthekine